Management of Chemotherapy‐induced Anemia (CIA) with Biosimilar Epoetin Alfa (Binocrit®) in Patients with Multiple Myeloma (MM): An Interim Analysis of an Ongoing French National Observational Study (The OncoBOS study)
| Autor: | Olivier Fitoussi, Lionel Karlin, Mario Ojeda-Urib, Laurent Voillat, Irina Voronina, Charles Dauriac, Camille Aubron-Olivier, Domitille Fernet |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Pediatrics
medicine.medical_specialty Blood transfusion Anemia business.industry medicine.medical_treatment Immunology Epoetin alfa Biosimilar Cell Biology Hematology medicine.disease Interim analysis Biochemistry Chemotherapy regimen medicine Observational study business Multiple myeloma medicine.drug |
| Zdroj: | Blood. 124:4001-4001 |
| ISSN: | 1528-0020 0006-4971 |
| DOI: | 10.1182/blood.v124.21.4001.4001 |
| Popis: | Background: OncoBOS is a national, prospective, non-interventional, longitudinal, observational study describing biosimilar epoetin alfa (Binocrit®) use in routine practice in France in patients receiving chemotherapy treatment (CT) for solid tumors, lymphoma or myeloma. This sub-analysis focuses on the management of CIA in patients with MM. Patients and methods: Patients ≥18 years with MM, CIA and eligible for treatment with Binocrit® were included in this analysis. Patients characteristics, data on CIA and its management and predominant factors considered by the physician in prescribing Binocrit® were recorded at baseline, 3-4 weeks and 12 (± 1) weeks later. Hemoglobin (Hb) outcomes assessed included the proportion of patients achieving a Hb increase ≥1 and ≥2 g/dL, and the mean Hb change from baseline. Results: 99 patients with MM (mean age 71.1 years) from 20 sites were recruited from September 2011 to April 2014. 54.5% of subjects were male. Mean and median baseline Hb levels were 9.4 g/dL and 10 g/dL, respectively. The mean increase in Hb level was 1.1 g/dL after 1 month and 2.2 g/dL after 3 months (p Conclusion: This sub-analysis indicates that Binocrit®, used in routine practice, is effective and well tolerated for the treatment of CIA in patients with MM receiving CT. Disclosures Voronina: Sandoz: Investigator Other. Ojeda-Urib:Sandoz: Honoraria. Dauriac:Sandoz: Investigator Other. Voillat:Sandoz: Investigator Other. Aubron-Olivier:Sandoz: Employment. Fernet:Sandoz: Employment. Karlin:Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees; Janssen: Honoraria, Membership on an entity's Board of Directors or advisory committees; Sandoz: Honoraria, Membership on an entity's Board of Directors or advisory committees. Fitoussi:Sandoz: Honoraria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|